Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)

May 12, 2025 8:21 AM EDT Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $10.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login